Browsing by Subject "Cpg Odn"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Thumbnail Image
    ItemOpen Access
    Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings
    (Taylor & Francis Inc., 2014-07) Gungor, B.; Yagci, F. C.; Gursel, I.; Gursel, M.
    Type I interferon inducers may potentially be engineered to function as antiviral and anticancer agents, or alternatively, vaccine adjuvants, all of which may have clinical applications. We recently described a simple strategy to convert a Toll-like receptor 9 (TLR9) agonist devoid of interferon alpha (IFN alpha) stimulating activity into a robust Type I interferon inducer with potent vaccine adjuvant activity.